Table III.
Univariate | Multivariate | |||||
---|---|---|---|---|---|---|
|
|
|||||
Baseline characteristic | HR | 95% CI | P-value | HR | 95% CI | P-value |
Age, years | 0.994 | (0.95–1.04) | 0.781 | 1.017 | (0.96–1.08) | 0.577 |
Cycles, n | 0.741 | (0.60–0.92) | 0.006 | 0.704 | (0.53–0.93) | 0.015 |
Hemoglobin, g/dl | 0.985 | (0.75–1.30) | 0.912 | 1.086 | (0.75–1.57) | 0.662 |
PSA, ng/ml | 1.000 | (1.00–1.00) | 0.872 | 1.000 | (1.00–1.00) | 0.936 |
PSA nadir, ng/ml | 1.002 | (1.00–1.01) | 0.243 | 1.002 | (1.00–1.01) | 0.402 |
Time to PSA nadir, months | 0.736 | (0.59–0.91) | 0.005 | 0.677 | (0.49–0.94) | 0.019 |
HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen. P<0.05 was considered to indicate a statistically significant result.